Precision Medicine Group
A Bethesda-based drug development and launch services firm, owned by Blackstone since 2020, that has agreed to be sold to McKesson for about $2.25 billion.
McKesson release, Aug 25, 2026- Valuation
- ~$2.25B McKesson's agreed purchase price, Aug 2026. Blackstone's 2020 entry was reported at $2.3B.
- Raised
- $275M the last sized outside round, Dec 2017; Blackstone's 2020 recap was not sized.
- Watch
- Sale pending needs regulatory clearance; no closing date given.
- Liquidity
- The sale no staff tender found; how employee units are paid out was not disclosed.
- AI
- Governed, early an AI ethics framework (Q1 2026) and a stake in an agentic patient services startup.
- Hiring
- 136 → 135 remote listings since Oct 10.
Paid by drug makers, from trial to launch.
Precision Medicine Group sells services to biotech and pharma companies in two groups. Precision for Medicine runs clinical trials as a CRO, plus specialty and central labs, sample kits and biospecimens. Precision AQ sells commercialization work: market access consulting, health economics, medical communications, marketing and PR. No revenue split has been published.
precisionmedicinegrp.com- 1Deep in oncology and biomarker-led trialsAbout 70% of its clinical trials are in oncology, with 2,500 trial and lab projects and five specialty labs in the US and Europe.precisionformedicine.com, checked Oct 31, 2026
- 2A launch shop the biggest drug makers usePrecision AQ says all 30 of the world's top pharma companies use it, and it has launched 450+ drugs.Precision AQ, Feb 17, 2026
- 3Molecule to market under one roofLabs, a global CRO, market access and commercialization in one group; McKesson cited those complementary capabilities as the reason to buy.McKesson release, Aug 25, 2026
- IQVIA$44.1Blisted, Oct 30 close
- Medpace$18.2Blisted, Oct 30 close
- ICON$16.3Blisted, Oct 30 close
- Syneos Health$7.10Bprivate, Sep 28
- Precision Medicine Group$2.25BSale to McKesson (pending), Aug 25
Private values are the last reported round; they can be stale. Listed values are market value. Bars start at zero.
Every round, and what its terms give away.
Precision Medicine Group is private, so there is no share price. What its investors paid, and on what terms, is the closest thing to one.
- $2.25B
- latest valuation, Sale to McKesson (pending) Aug 25
- 3,500
- employees, as reported
Not disclosed by PMG, Blackstone or McKesson.
PMG, Oct 1, 2024 (employees)Post-money valuations as reported. The line starts at zero. Rounds without a reported valuation are left off.
- Aug 25Sale to McKesson (pending)$2.25B at $2.25BLed by McKesson (buyer). About 100% of the company, if all new sharesDefinitive agreement; subject to regulatory clearances. Blackstone was seller; Centerview and Simpson Thacher advised the sell side.McKesson release, Aug 25, 2026
- Nov 20Blackstone majority recapitalizationat $2.30BLed by BlackstoneTerms not disclosed by the parties; $2.3B valuation as reported by The Deal. Founders, Berkshire Partners, TPG Growth, Oak HC/FT and Vida Ventures stayed in.Debevoise, Nov 20, 2020; The Deal (valuation)
- Nov 18Senior secured loansLed by Morgan Stanley, Goldman Sachs, MizuhoDebt arranged to fund the Blackstone deal; size not disclosed.Milbank, Nov 18, 2020
- Dec 19Growth equity$275MLed by Berkshire Partners and TPG GrowthFounders, management, Oak Investment Partners and J.H. Whitney joined. TPG Growth first invested in 2015.BioSpace, Dec 19, 2017
- Exit above the last price?Roughly flat. McKesson pays about $2.25B; The Deal reported Blackstone's 2020 entry at $2.3B. The two figures may not be on the same basis (debt, equity).The Deal, Aug 25, 2026Flag
- How much the deal sellsAll of it: McKesson signed to acquire Precision Medicine Group, LLC, which will report inside its Oncology and Multispecialty segment.McKesson release, Aug 25, 2026Clear
- Time since the last dealAlmost six years of Blackstone ownership; a sale process with Centerview was reported in Jan 2026.The Deal, Aug 25, 2026Clear
- Unusual terms or heavy debt?The 2020 deal used senior secured bank debt of undisclosed size. Net debt and the equity value inside the $2.25B price were not disclosed.Milbank, Nov 18, 2020Open
- Who is buyingAn outside strategic buyer, McKesson (NYSE: MCK), not another PE fund.Simpson Thacher, Aug 25, 2026Clear
- Can staff sell shares?No tender offer found. The company is an LLC; how any employee incentive units are paid in the sale was not disclosed.McKesson release, Aug 25, 2026Open
- Layoffs in the last 12 months?None found in company releases or press searches. Integration after closing is the period to watch.PMG press releases, checked Oct 31, 2026Clear
Clear: checked, nothing found. Flag: found, with the source. Open: could not be checked.
No IPO. Definitive agreement to be acquired by McKesson for about $2.25B, pending regulatory clearances.
What the record says, and what we think it means.
The fact is the source's. The read, in italics, is ours.
- 01Neutral
Agreed to be sold to McKesson for about $2.25 billion.
McKesson release, Aug 25, 2026Signed Aug 2026. PMG will sit in McKesson's Oncology and Multispecialty segment. Closing needs regulatory clearance; no date given.
A strategic owner with deep pockets replaces a PE fund that needed an exit. Until it closes, expect little change; after, expect new reporting lines and systems.
- 02Watch
The sale price is about what Blackstone reportedly paid.
The Deal, Aug 25, 2026$2.25B now versus a $2.3B valuation reported for Blackstone's 2020 majority deal.
Six years of ownership without a visible step-up suggests slower growth than hoped, or a lot of debt inside the price. Neither number is fully disclosed, so hedge.
- 03Neutral
Blackstone ran an auction for most of 2026.
The Deal, Aug 25, 2026The Deal reported in Jan 2026 that Blackstone hired Centerview to sell PMG. McKesson signed in Aug.
An eight-month process ending with one strategic buyer. Normal for a PE exit.
- 04Neutral
A CRO operator was brought in as CEO before the sale.
PMG, Oct 1, 2024Margaret Keegan, ex-COO of PRA Health Sciences through its sale to ICON and a former IQVIA president, became CEO in Oct 2024. Co-founder Mark Clein moved to executive chair.
She has run a CRO through a sale before. Looking back, the hire fits an exit plan.
- 05Neutral
Most of the top team is new since late 2024.
PMG press releasesNew CFO and a new Chief Transformation and Strategy Officer (Oct 2024), CITO (Apr 2025) and Chief People Officer (Sept 2025).
A fresh team built for the sale. Several roles could overlap with McKesson's after closing.
- 06Neutral
Bought with bank debt in 2020.
Milbank, Nov 18, 2020Morgan Stanley, Goldman Sachs and Mizuho arranged senior secured loans for the Blackstone deal. The amount was not disclosed.
Typical PE leverage. A strategic buyer usually refinances it, which removes debt pressure on the business.
- 07Good
Bought into an agentic patient services startup.
Precision AQ, Nov 18, 2025In Nov 2025 Precision AQ invested in Phluence, which uses generative AI to automate therapy access work like enrollment and reverification. Amount not disclosed.
A hedge against AI automating the labor-heavy patient hub work its clients buy today.
- 08Neutral
Seven in ten of its trials are cancer trials.
precisionformedicine.com, checked Oct 31, 2026Precision for Medicine says about 70% of its clinical trials are in oncology, and it has three ex-FDA oncology leaders.
A clear niche, and the reason McKesson's oncology unit wants it. Also concentration in one therapy area's funding cycle.
Other is paid 8% over market. Sales, 54% under.
We save every company's roles, pay by team and level, AI share and churn every day, so each month this page can say more. Sparklines use their own scale.
Can AI agents do business with Precision Medicine Group?
We checked the agent payment programs, developer docs and site rules an AI assistant would meet.
Readable, not built for agents. Open robots.txt, no llms.txt, no MCP.
Still Remote read- YesLets AI crawlers read its sitesprecisionmedicinegrp.com blocks only /wp-admin/. Precision for Medicine and Precision AQ block only HubSpot preview paths. No AI bot named.checked Oct 31, 2026
- YesCan assistants read its job openingscareers.precisiongroupcompanies.com allows all bots.checked Oct 31, 2026
- Not foundAn llms.txt file for AI tools404 on precisionmedicinegrp.com, precisionformedicine.com and precisionaq.com.checked Oct 31, 2026
- Not foundAn MCP server, API or agent toolkitNo public API or agent integration found. Services are sold through people and projects.checked Oct 31, 2026
- MixedAgent products for clientsOwns a stake in Phluence, an agentic patient access platform; its own named tools (DecodeRx, PatientLens) are not described as agents.Precision AQ, Nov 18, 2025
Where Precision Medicine Group puts AI to work.
- 1An AI rulebook before AI productsIts Q1 2026 AI Ethical Framework says AI should support, not replace, human judgment, with named owners for each AI system and governance by senior leaders.PMG AI Ethical Framework, Q1 2026
- 2A senior AI hire in commercializationPrecision AQ named an SVP of Data Strategy and AI in Feb 2026 to push AI-enabled delivery for clients.Precision AQ, Feb 17, 2026
- 3No AI-linked job cuts announcedNo release or report ties layoffs to AI. Its framework frames AI as an aid to staff.PMG press releases, checked Oct 31, 2026
More listings than on Sep 7, led by clinical.
What has to be true for $2.25 billion to hold?
Precision Medicine Group does not publish revenue, so the starting number is your assumption, not ours. A way to think, not a forecast, and not investment advice.
At 25x, Precision Medicine Group needs $90 million of revenue to be worth $2.25 billion. Your world gets there with $176 million, so the next round likely prices above the last.
$100,000 of equity valued at the $2.25B Sale to McKesson (pending) price would be worth about $196,000 on paper in this world, before dilution from new rounds, taxes and vesting. Private shares only turn into cash at a sale, an IPO or a tender offer.
A way to think, not a forecast, and not investment advice.
McKesson release, Aug 25, 2026The signals, and which way they push.
- TailwindA long-term owner is coming.
McKesson is buying the whole company to strengthen trial execution and commercialization in oncology, instead of another PE flip.
- TailwindCancer drug work is its core.
About 70% of trials are oncology, and it hired ex-FDA oncology leaders.
- HeadwindIntegration brings change.
A new owner, a pending regulatory review, and a new top team since 2024 mean roles and reporting lines may shift.
- HeadwindThe CRO world is consolidating.
Thermo Fisher bought Clario for $8.875B in 2026, and sponsors are moving to fewer end-to-end vendors.
Where Precision Medicine Group ends up, if we had to bet.
Our calls, not facts. Each one is tied to something that already happened, so you can judge the reasoning.
- 1
By 2031 the Precision name is gone, folded into McKesson's oncology brands.
Coin flip 50%M&APMG will report inside McKesson's Oncology and Multispecialty segment. Strategic buyers often keep a known brand for a few years, then merge it.
McKesson release, Aug 25, 2026 - 2
PMG lists on its own by 2036.
Long shot 16%IPOIt is being sold to a strategic buyer, not floated. A spin-off would need McKesson to reverse course.
McKesson release, Aug 25, 2026 - 3
McKesson sells or splits off the commercialization arm, Precision AQ, by 2032.
Coin flip 50%ProductsMcKesson's stated reason is clinical research and trial execution. The marketing and medical communications work fits less naturally inside a drug distributor.
McKesson release, Aug 25, 2026 - 4
AI agents handle most routine patient access and trial admin work PMG sells today.
Likely 72%AIIt already invested in Phluence to automate hub workflows and named an AI lead. Its framework keeps humans on decisions, not paperwork.
Precision AQ, Nov 2025 - 5
Fewer, bigger CROs win most oncology trial work, and PMG is one of them only as part of McKesson.
Likely 72%CompetitionThermo Fisher and Clario, Syneos going private, and now McKesson and PMG show the shift. Sponsors want fewer end-to-end vendors.
PharmTech, Aug 25, 2026
Read by the Still Remote research agent on November 1, 2026 from the sources linked on this page. Facts and scenarios only, not investment advice.